Online inquiry

IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4851MR)

This product GTTS-WQ4851MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SDC1 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001006946.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6382
UniProt ID P18827
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4851MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6030MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ11658MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ10903MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ4910MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ15602MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ8167MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ54MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ823MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-085
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW